Literature DB >> 11432976

Expression and role of phosphodiesterase 6 in the chicken pineal gland.

F Morin1, C Lugnier, J Kameni, P Voisin.   

Abstract

The chicken pineal gland is directly photosensitive, with light causing an inhibition of melatonin synthesis. A possible role of phosphodiesterase 6 (PDE6, the primary effector of retinal phototransduction) in mediating this response was investigated. RT-PCR, DNA sequencing and northern blots revealed the presence of RNA encoding both catalytic and regulatory subunits of PDE6 in the chicken pineal gland. Both rod and cone forms of PDE6 subunits mRNA were detected. The concentration of the transcripts encoding PDE6 catalytic subunits peaked at night. Western blot analysis of chicken pineal proteins with an antibody directed against the catalytic subunits of bovine rod PDE6 identified a single immunoreactive protein of 97 kDa. Anion exchange chromatography of chicken pineal soluble proteins revealed a peak of PDE6 activity that accounted for about 30% of cyclic GMP-hydrolysis. In cultured chick pineal glands, arylalkylamine N-acetyltransferase (AA-NAT), the rate-limiting enzyme of melatonin synthesis, was protected from inhibition by light when selective PDE5/6 inhibitors (zaprinast, DMPPO) were added to the culture medium. PDE5/6 inhibitors did not affect AA-NAT activity in the dark. In contrast, a general PDE inhibitor (IBMX) increased AA-NAT in a light-independent manner. Together, the data indicate that rod and cone forms of PDE6 are expressed in chick pineal cells and that this enzyme plays a role in the inhibition of melatonin synthesis by light.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432976     DOI: 10.1046/j.1471-4159.2001.00407.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 3.  The retinal cGMP phosphodiesterase gamma-subunit - a chameleon.

Authors:  Lian-Wang Guo; Arnold E Ruoho
Journal:  Curr Protein Pept Sci       Date:  2008-12       Impact factor: 3.272

Review 4.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

5.  PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.

Authors:  Ayse Sahaboglu; Naoyuki Tanimoto; Jasvir Kaur; Javier Sancho-Pelluz; Gesine Huber; Edda Fahl; Blanca Arango-Gonzalez; Eberhart Zrenner; Per Ekström; Hubert Löwenheim; Mathias Seeliger; François Paquet-Durand
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

Review 6.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

7.  Phosphodiesterase 6C, cGMP-specific cone alpha'.

Authors:  Karyn B Cahill; Rick H Cote
Journal:  AFCS Nat Mol Pages       Date:  2011-06-03

8.  A novel role for a Drosophila homologue of cGMP-specific phosphodiesterase in the active transport of cGMP.

Authors:  Jonathan P Day; Miles D Houslay; Shireen-A Davies
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

9.  Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.

Authors:  Hongli Dong; Kevin P Claffey; Stefan Brocke; Paul M Epstein
Journal:  Springerplus       Date:  2013-12-18

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.